lifestyle.longislandreport.org

Author: BIOMARIN PHARMACEUTICAL INC.

BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

March 12, 2026
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

March 12, 2026
U.S. Food and Drug Administration Approves BioMarin’s PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)

March 2, 2026
U.S. Food and Drug Administration Approves BioMarin’s PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)

March 2, 2026
BioMarin to Participate in Four Upcoming Investor Conferences in March

February 24, 2026
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results

February 24, 2026
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET

February 18, 2026
BioMarin Announces Closing of Private Offering of Senior Notes

February 17, 2026
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility

February 7, 2026
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility

February 3, 2026